Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMANI-2: Switch Maintenance in Advanced Gastroesophageal Adenocarcinoma
NCT07763171Phase 3Not yet recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 3
01
Overview
A Phase 3 trial of Paclitaxel Micelles for Injection, ramucirumab in gastroesophageal adenocarcinoma, sponsored by Gruppo Oncologico Nord Ovest. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Paclitaxel Micelles for Injectionramucirumab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT07763171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07763171.